Please assess the completion status of the following clinical trial:

Trial Title: Lot-to-lot Consistency of Quadrivalent Influenza Vaccine (Split Virion), Inactivated

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy subjects aged 9-59 years;~* The subjects and/or guardians can understand and voluntarily sign the informed consent form (For subjects aged 9-17 years, both subjects and guardians need to sign the informed consent form).~* Proven legal identity.~Exclusion Criteria:~* Received seasonal influenza vaccine for 2022-2023 influenza season, or had an influenza vaccine schedule during the study;~* Suffering from seasonal influenza in the past 6 moths;~* Women of childbearing age (menarche to premenopause) are pregnant(including positive urine pregnancy test), breastfeeding or planning pregnancy within 1 month;~* Patients with fever on the day of vaccination,underarm body temperature\>37.2 ℃;~* History of asthma, allergy to vaccines or vaccine components, and serious adverse reactions to vaccines, such as urticaria, dyspnea, and angioneurotic edema;~* Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.~* Severe chronic diseases,such as severe cardiovascular diseases, hypertension(Systolic blood pressure ≥140mmHg and/or diastolic blood pressure ≥90mmHg) and diabetes that cannot be controlled by drugs, liver or kidney diseases,malignant tumors, etc.;~* Severe neurological disease (epilepsy, convulsions or convulsions) or mental illness;~* Autoimmune disease or immune deficiency/immunosuppression;~* Thyroid disease or history of thyroidectomy,absence of spleen, functional functional asplenia,and absence of spleen or splenectomy as a result of any condition;~* Diagnosed abnormal blood coagulation function (eg, lack of blood coagulation factors, blood coagulopathy, abnormal platelets) or obvious bruising or blood coagulation;~* Immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids(excluding allergic rhinitis corticosteroid spray therapy, acute noncomplicated dermatitis superficial corticosteroid therapy) in the past 6 months;~* A long history of alcohol or drug abuse;~* Onset of various acute or chronic diseases within 7 days prior to the study;~* Receipt of blood products within in the past 3 months;~* Receipt of other investigational drugs within 30 days prior to receiving the investigational vaccine;~* Receipt of attenuated live vaccines or COVID-19 vaccines in the past 14 days,receipt of inactivated or subunit vaccines in the past 7 days;~* The subjects participated in other clinical trials during the follow-up period or will be planned to participate other clinical trials during the follow-up period;~* According to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial.

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: 59 Years
- Healthy Volunteers: t

Study Arms:
- Quadrivalent Influenza Vaccine (Split Virion), inactivated Lot 1 (Type: EXPERIMENTAL): 420 participants including 120 subjects aged 9-17 years and 300 subjects aged 18-59 years will receive one dose of quadrivalent influenza vaccine of commercial scale production lot 1.
- Quadrivalent Influenza Vaccine (Split Virion), inactivated Lot 2 (Type: EXPERIMENTAL): 420 participants including 120 subjects aged 9-17 years and 300 subjects aged 18-59 years will receive one dose of quadrivalent influenza vaccine of commercial scale production lot 2.
- Quadrivalent Influenza Vaccine (Split Virion), inactivated Lot 3 (Type: EXPERIMENTAL): 420 participants including 120 subjects aged 9-17 years and 300 subjects aged 18-59 years will receive one dose of quadrivalent influenza vaccine of commercial scale production lot 3.

Based on this trial design, predict the completion outcome and termination type (if applicable).